Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05866471 · ClinicalTrials.gov registry record · Phase 1
The ENHANCE Study: taVNS and Psilocybin
A Phase 1 study of Healthy and Psychedelic Experiences, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT05866471 is a Phase 1 study of Healthy and Psychedelic Experiences that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 108 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05866471, a Phase 1 study of Healthy and Psychedelic Experiences, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance the long-term beneficial behavioral effects of psilocybin when compared to sham taVNS or no VNS by allowing memory for insights gained during the psychedelic experience to remain vivid after they will have faded in subjects who receive psilocybin followed by sham taVNS or no VNS.
Conditions Studied
Interventions
- DRUG Psilocybin
- DEVICE Transcutaneous auricular Vagus Nerve Stimulation (taVNS)
- BEHAVIORAL Psychosocial Support Alone
- OTHER Sham taVNS
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2025-01-27 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05866471
The ClinicalTrials.gov registry entry for NCT05866471 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (83% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Psilocybin is the first listed.
NCT05866471 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05866471 about?
NCT05866471 is a clinical study titled "The ENHANCE Study: taVNS and Psilocybin". This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance the long-term beneficial behavioral effects of psilocybin when compared...
What is the current status of trial NCT05866471?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2025-01-27. Estimated completion is 2028-01.
What conditions does trial NCT05866471 study?
This clinical trial studies the following conditions: Healthy, Psychedelic Experiences, Vagus Nerve Stimulation.
What interventions are being tested in trial NCT05866471?
The interventions under investigation include: Psilocybin (DRUG), Transcutaneous auricular Vagus Nerve Stimulation (taVNS) (DEVICE), Psychosocial Support Alone (BEHAVIORAL), Sham taVNS (OTHER).
Who is sponsoring clinical trial NCT05866471?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05866471 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.